HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ATGAM safely and effectively. See full prescribing information for ATGAM.
ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine]), sterile solution for intravenous use only
Initial U.S. Approval: 1981
See full prescribing information for complete boxed warning.
Antithymocyte globulins can cause anaphylaxis when injected intravenously. Although ATGAM is processed to reduce the level of antibodies that will react to non-T cells, physicians should be prepared for the potential risk of anaphylaxis and monitor patients for signs and symptoms during infusion.
INDICATIONS AND USAGE
ATGAM is an immunoglobulin G indicated for:
DOSAGE AND ADMINISTRATION
Intravenous use only.
DOSAGE FORMS AND STRENGTHS
WARNINGS AND PRECAUTIONS
The most common (>10%) adverse reactions are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia. (6.1)
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION.
ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine]) Highlights
No Current Announcements.
Report an Adverse Event